Edition:
United States

CytomX Therapeutics Inc (CTMX.O)

CTMX.O on Nasdaq

14.39USD
22 Jun 2017
Change (% chg)

$0.13 (+0.91%)
Prev Close
$14.26
Open
$14.35
Day's High
$14.75
Day's Low
$14.20
Volume
529,833
Avg. Vol
256,414
52-wk High
$20.02
52-wk Low
$9.10

CTMX.O

Chart for CTMX.O

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $524.05
Shares Outstanding(Mil.): 36.75
Dividend: --
Yield (%): --

Financials

  CTMX.O Industry Sector
P/E (TTM): -- 244.33 18.98
EPS (TTM): -1.41 -- --
ROI: -32.39 -7.97 -5.09
ROE: -54.83 -9.96 -4.32

BRIEF-Cytomx announces management team changes

* Bob Goeltz, chief financial officer, has decided to leave company to pursue new opportunities

May 15 2017

BRIEF-CytomX Therapeutics qtrly loss per share $ 0.23

* Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S

May 05 2017

BRIEF-Cytomx Therapeutics announces proposed resale of up to 10.9 mln shares by selling stockholders

* Cytomx Therapeutics Inc - files for proposed resale or other disposition of up to 10.9 million shares of co by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

Mar 09 2017

BRIEF-Cytomx announces full-year 2016 financial results

* Cytomx announces full-year 2016 financial results Source text for Eikon: Further company coverage:

Mar 02 2017

BRIEF-Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial

* Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial Source text for Eikon: Further company coverage:

Feb 02 2017

More From Around the Web

Earnings vs. Estimates